| Select | PubMed ID | Description |
| 7694084 | Mol Immunol. 1993 Oct;30(15):1323-9.
T cell clones specific for Bet v I, the major birch pollen allergen, crossreact
with the major allergens of hazel, Cor a I, and alder, Aln g I.
Ebner C(1), Ferreira F, Hoffmann K, Hirschwehr R, Schenk S, Szépfalusi Z,
Breiteneder H, Parronchi P, Romagnani S, Scheiner O, et al.
|
| 7797268 | Immunogenetics. 1995;42(1):53-8.
Diversity of TCRAV and TCRBV sequences used by human T-cell clones specific for a
minimal epitope of Bet v 1, the major birch pollen allergen.
Breiteneder H(1), Scheiner O, Hajek R, Hulla W, Hüttinger R, Fischer G, Kraft D,
Ebner C.
|
| 7925389 | Eur J Biochem. 1994 Sep 1;224(2):717-22.
Four recombinant isoforms of Cor a 1, the major allergen of hazel pollen, show
different reactivities with allergen-specific T-lymphocyte clones.
Schenk S(1), Hoffmann-Sommergruber K, Breiteneder H, Ferreira F, Fischer G,
Scheiner O, Kraft D, Ebner C.
|
| 8366100 | J Biol Chem. 1993 Sep 15;268(26):19574-80.
Purification and characterization of recombinant Bet v I, the major birch pollen
allergen. Immunological equivalence to natural Bet v I.
Ferreira FD(1), Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C,
Sommergruber W, Steiner R, Bohle B, Sperr WR, Valent P, et al.
|
| 8627171 | J Exp Med. 1996 Feb 1;183(2):599-609.
Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the
major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for
immunotherapy.
Ferreira F(1), Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R,
Hoffmann-Sommergruber K, Scheiner O, Kraft D, Breitenbach M, Rheinberger HJ,
Ebner C.
|
| 8936599 | Protein Expr Purif. 1996 Nov;8(3):365-73.
Characterization of purified recombinant Bet v 1 with authentic N-terminus,
cloned in fusion with maltose-binding protein.
Spangfort MD(1), Ipsen H, Sparholt SH, Aasmul-Olsen S, Larsen MR, Mørtz E,
Roepstorff P, Larsen JN.
|
| 9095250 | Adv Exp Med Biol. 1996;409:251-4.
Characterisation of recombinant isoforms of birch pollen allergen Bet v 1.
Spangfort MD(1), Ipsen H, Sparholt SH, Aasmul-Olsen S, Osmark P, Poulsen FM,
Larsen M, Mørtz E, Roepstorff P, Larsen JN.
|
| 9067529 | Clin Exp Immunol. 1997 Mar;107(3):536-41.
Modulation of the allergic immune response in BALB/c mice by subcutaneous
injection of high doses of the dominant T cell epitope from the major birch
pollen allergen Bet v 1.
Bauer L(1), Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner
C.
|
| 9120011 |
J Clin Invest. 1997 Apr 1;99(7):1673-81.
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic
T cell epitope-containing fragments: candidates for a novel form of specific
immunotherapy.
Vrtala S(1), Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR,
Valent P, Ebner C, Kraft D, Valenta R.
|
| 9363909 | Int Arch Allergy Immunol. 1997 Nov;114(3):272-7.
Heterogeneity in the polyclonal T cell response to birch pollen allergens.
Dormann D(1), Montermann E, Klimek L, Weber B, Ebner C, Valenta R, Kraft D,
Reske-Kunz AB.
|
| 9373319 | Immunotechnology. 1996 Jun;2(2):103-13.
Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell
surface layers (S-layers).
Jahn-Schmid B(1), Graninger M, Glozik M, Küpcü S, Ebner C, Unger FM, Sleytr UB,
Messner P.
|
| 9472988 | FASEB J. 1998 Feb;12(2):231-42.
Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential
use of hypoallergenic variants for immunotherapy.
Ferreira F(1), Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R,
Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger HJ, Scheiner O.
|
| 9472674 | Clin Exp Immunol. 1998 Jan;111(1):144-51.
Effects of adjuvants on the immune response to allergens in a murine model of
allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the
major birch pollen allergen.
Wiedermann U(1), Jahn-Schmid B, Fritsch R, Bauer L, Renz H, Kraft D, Ebner C.
|
| 9472988 | FASEB J. 1998 Feb;12(2):231-42.
Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential
use of hypoallergenic variants for immunotherapy.
Ferreira F(1), Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R,
Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger HJ, Scheiner O.
|
| 10452773 | J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):466-72.
Birch pollen-related foods trigger atopic dermatitis in patients with specific
cutaneous T-cell responses to birch pollen antigens.
Reekers R(1), Busche M, Wittmann M, Kapp A, Werfel T.
|
| 10589007 | J Allergy Clin Immunol. 1999 Dec;104(6):1239-43.
Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch
pollen.
Arquint O(1), Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ.
|
| 11086111 | J Immunol. 2000 Dec 1;165(11):6653-9.
T cell epitope-containing hypoallergenic recombinant fragments of the major birch
pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S(1), Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R.
|
| 12569978 | Clin Exp Allergy. 2002 Nov;32(11):1583-8.
Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1,
induces B cell responses to the natural antigen using bystander T cell help.
Schöll I(1), Wiedermann U, Förster-Waldl E, Ganglberger E, Baier K,
Boltz-Nitulescu G, Scheiner O, Ebner C, Jensen-Jarolim E.
|
| 15722633 | Int Arch Allergy Immunol. 2005 Mar;136(3):239-49. Epub 2005 Feb 16.
Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against
birch pollen allergy.
Batard T(1), Didierlaurent A, Chabre H, Mothes N, Bussières L, Bohle B, Couret
MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P,
Krauth MT, André C, Valenta R, Moingeon P.
|
| 15990797 | J Allergy Clin Immunol. 2005 Jul;116(1):213-9.
Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen
and important for cross-reactivity with Bet v 1-related food allergens.
Jahn-Schmid B(1), Radakovics A, Lüttkopf D, Scheurer S, Vieths S, Ebner C, Bohle
B.
|
| 17202384 | J Immunol. 2007 Jan 15;178(2):1189-98.
Functional analysis of birch pollen allergen Bet v 1-specific regulatory T cells.
Nagato T(1), Kobayashi H, Yanai M, Sato K, Aoki N, Oikawa K, Kimura S, Abe Y,
Celis E, Harabuchi Y, Tateno M.
|
| 17204315 | J Allergy Clin Immunol. 2007 Apr;119(4):937-43. Epub 2007 Jan 3.
Successful sublingual immunotherapy with birch pollen has limited effects on
concomitant food allergy to apple and the immune response to the Bet v 1 homolog
Mal d 1.
Kinaciyan T(1), Jahn-Schmid B, Radakovics A, Zwölfer B, Schreiber C, Francis JN,
Ebner C, Bohle B.
|
| 17912007 | Int Arch Allergy Immunol. 2008;145(3):193-206. Epub 2007 Oct 2.
Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate
for allergen-specific immunotherapy.
Kahlert H(1), Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.
|
| 18354173 | J Immunol. 2008 Apr 1;180(7):4514-22.
Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic
individuals using MHC class II peptide tetramers.
Van Overtvelt L(1), Wambre E, Maillère B, von Hofe E, Louise A, Balazuc AM, Bohle
B, Ebo D, Leboulaire C, Garcia G, Moingeon P.
|
| 20005001 | Immunobiology. 2010 Nov;215(11):903-9. doi: 10.1016/j.imbio.2009.11.003. Epub
2009 Dec 11.
Differential T-cell responses and allergen uptake after exposure of dendritic
cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U(1), Balazs N, Hoffmann-Sommergruber K, Radauer C, Hafner C, Wallner M,
Ferreira F, Grössinger R, de Jong EC, Wagner S, Breiteneder H.
|
| 20132976 | J Allergy Clin Immunol. 2010 Mar;125(3):711-8, 718.e1-718.e2. doi:
1016/j.jaci.2009.10.052. Epub 2010 Feb 4.
Naturally processed T cell-activating peptides of the major birch pollen
allergen.
Mutschlechner S(1), Egger M, Briza P, Wallner M, Lackner P, Karle A, Vogt AB,
Fischer GF, Bohle B, Ferreira F.
|
| 21215346 | Vaccine. 2011 Mar 3;29(11):2140-8. doi: 10.1016/j.vaccine.2010.12.080. Epub 2011
Jan 5.
Genetic engineering of trimers of hypoallergenic fragments of the major birch
pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S(1), Fohr M, Campana R, Baumgartner C, Valent P, Valenta R.
|
| 21420160 | J Allergy Clin Immunol. 2011 Jun;127(6):1571-8.e9. doi:
1016/j.jaci.2011.01.064. Epub 2011 Mar 21.
Reshaping the Bet v 1 fold modulates T(H) polarization.
Wallner M(1), Hauser M, Himly M, Zaborsky N, Mutschlechner S, Harrer A, Asam C,
Pichler U, van Ree R, Briza P, Thalhamer J, Bohle B, Achatz G, Ferreira F.
|
| 22973879 | Allergy. 2012 Nov;67(11):1375-82. doi: 10.1111/all.12016. Epub 2012 Sep 13.
A hypoallergenic variant of the major birch pollen allergen shows distinct
characteristics in antigen processing and T-cell activation.
Kitzmüller C(1), Wallner M, Deifl S, Mutschlechner S, Walterskirchen C, Zlabinger
GJ, Ferreira F, Bohle B.
|
| 22691258 | J Biol Regul Homeost Agents. 2012 Jan-Mar;26(1 Suppl):S113-7.
Patients with oral allergic syndrome to apple have intense proliferative response
to BET V 1.
Ciprandi G(1), Fenoglio G, Kalli F, De Amici M, Leonardi S, Miraglia Del Giudice
M, Salpietro C, La Rosa M, Caimmi S, Marseglia GL.
|
| 24447086 | Clin Exp Allergy. 2014 Feb;44(2):278-87. doi: 10.1111/cea.12216.
Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides
lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell
responses via blocking antibodies in a murine model for birch pollen allergy.
Linhart B(1), Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R.
|
| 25126882 | PLoS One. 2014 Aug 15;9(8):e104520. doi: 10.1371/journal.pone.0104520.
eCollection 2014.
The impact of nitration on the structure and immunogenicity of the major birch
pollen allergen Bet v 1.0101.
Ackaert C(1), Kofler S(1), Horejs-Hoeck J(1), Zulehner N(2), Asam C(3), von
Grafenstein S(4), Fuchs JE(4), Briza P(1), Liedl KR(4), Bohle B(2), Ferreira
F(3), Brandstetter H(1), Oostingh GJ(1), Duschl A(1).
|
| 27222434 | Allergy. 2017 Feb;72(2):244-251. doi: 10.1111/all.12938. Epub 2016 Jun 10.
Characterization of the T-cell response to Dau c 1, the Bet v 1-homolog in
carrot.
Zulehner N(1), Nagl B(1), Briza P(2), Roulias A(2), Ballmer-Weber B(3), Zlabinger
GJ(4), Ferreira F(2), Bohle B(1).
|
| 29885257 | Allergy. 2018 Oct;73(10):2080-2082. doi: 10.1111/all.13498. Epub 2018 Jul 2.
Major hazelnut and peanut allergens are potent in basophil activation and
cross-react at T-cell level.
Masthoff LJN(1), Pasmans SGMA(1), van Doorn H(1), den Hartog Jager CF(1),
Geneugelijk K(1), Knol EF(1)(2), Bruijnzeel-Koomen CAFM(1), Lidholm J(3), Knulst
AC(1), Hoffen E(1).
|
| 30887520 | Allergy. 2019 Mar 19. doi: 10.1111/all.13779. [Epub ahead of print]
Sublingual immunotherapy with recombinant Mal d 1 downregulates the
allergen-specific Th2 response.
Kitzmüller C(1), Jahn-Schmid B(1), Kinaciyan T(2), Bohle B(1).
|
